ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Repke J. Snijder
Aart Brutel de la Rivière
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Snijder, R. J.
Right arrow Articles by van den Bosch, J. M. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Snijder, R. J.
Right arrow Articles by van den Bosch, J. M. M.

Ann Thorac Surg 1998;65:212-216
© 1998 The Society of Thoracic Surgeons

Original Articles: General Thoracic

Survival in Resected Stage I Lung Cancer With Residual Tumor at the Bronchial Resection Margin

Repke J. Snijder, MD, Aart Brutel de la Rivière, MD, PhD, Hans J. J. Elbers, MD, Jules M. M. van den Bosch, MD

Department of Pulmonology, Sint Antonius Hospital, Nieuwegein, the Netherlands
Department of Thoracic Surgery, Sint Antonius Hospital, Nieuwegein, the Netherlands
Department of Pathology, Sint Antonius Hospital, Nieuwegein, the Netherlands

Accepted for publication July 23, 1997.

Dr Snijder, Department of Pulmonology, Sint Antonius Hospital, PO Box 2500, 3430 EM Nieuwegein, the Netherlands.

Background. Sometimes microscopic residual tumor is found at the bronchial resection margin despite an apparently complete resection of lung cancer. This may adversely affect the patient’s prognosis. Its impact on survival is unclear.

Methods. The records of 834 patients with resected stage I non–small cell lung cancer were studied. Patients with complete resection were assigned to the complete resection group (n = 802); patients with microscopic residual tumor at the bronchial resection margin that was accepted were assigned to the residual tumor group (n = 23). Residual tumor was classified as carcinoma in situ, mucosal residual disease, or peribronchial residual disease.

Results. The 5-year survival in the patients in the complete resection group was 54%; it was 58% in the residual tumor group with carcinoma in situ and 27.3% in the residual tumor group with invasive tumor (mucosal residual disease or peribronchial residual disease). The difference in survival between patients in the complete resection group and patients in the residual tumor group with invasive tumor was significant (p = 0.03).

Conclusions. The presence of mucosal or peribronchial residual disease, but not carcinoma in situ, at the bronchial resection margin in patients with stage I non–small cell lung cancer has an adverse effect on survival.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1998 by The Society of Thoracic Surgeons.